Starpharma Holdings EBITDA 2011-2021 | SPHRY
Starpharma Holdings ebitda from 2011 to 2021. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Starpharma Holdings Annual EBITDA
(Millions of US $) |
| 2021 |
$-14 |
| 2020 |
$-9 |
| 2019 |
$-10 |
| 2018 |
$-6 |
| 2017 |
$-11 |
| 2016 |
$-17 |
| 2015 |
$-15 |
| 2014 |
$-12 |
| 2013 |
$-5 |
| 2012 |
$-14 |
| 2011 |
$-8 |
Starpharma Holdings Quarterly EBITDA
(Millions of US $) |
| 2021-06-30 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2019-06-30 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| 2011-06-30 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.216B |
$0.002B |
|
Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia.
|
